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Gap junctionConnexins are transmembrane proteins that form gap junction- and hemi-channels. Once inserted
into the membrane, hemi-channels (connexons) allow for diffusion of ions and small molecules
(<1 kDa) between the extracellular space and the cytosol. Gap junction channels allow diffusion of
similar molecules between the cytoplasms of adjacent cells. The expression and function of connex-
ins in blood vessels has been intensely studied in the last few decades. In contrast, only a few studies
paid attention to lymphatic vessels; convincing in vivo data with respect to expression patterns of
lymphatic connexins and their functional roles have only recently begun to emerge. Interestingly,
mutations in connexin genes have been linked to diseases of lymphatic vasculature, most notably
primary and secondary lymphedema. This review summarizes the available data regarding lympha-
tic connexins. More speciﬁcally it addresses (i) early studies aimed at presence of gap junction-like
structures in lymphatic vessels, (ii) more recent studies focusing on lymphatic connexins using
genetically engineered mice, and (iii) results of clinical studies that have reported lymphedema-
linked mutations in connexin genes.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Connexins form a protein family consisting of 21 members in
humans and 20 members in mice [1,2]. These transmembrane pro-
teins form hexamers in either the endoplasmic reticulum (ER) or
the Golgi apparatus that, once inserted in the membrane, can func-
tion as a hemi-channel (connexon) or as part of a gap junction
channel (Fig. 1). Connexons allow diffusion of small soluble mole-
cules (<1000 Da, e.g. ATP, Ca2+, cAMP and IP3) from the cytosol to
the extracellular space and vice versa [3]. Gap junctions permit dif-
fusion of similarly sized molecules between the cytoplasms of
adjacent cells [4]. Most cell types express connexins and many
cells express more than one connexin subtype. Their (patho-)phys-
iological contribution to intercellular communication and synchro-
nization of tissue responses in, for example, the brain, heart,
arterial endothelium and glomeruli has been extensively studied.
The results of these studies have been summarized elsewhere in
excellent reviews (see e.g. [5–9]). However, their in vivo expression
in lymphatic vessels has only recently been established and their
function in lymphatics remains elusive [10,11].2. Anatomy and physiology of lymphatic vessels
Components of the lymphatic system have already been
reported by Hippocrates (an ancient Greek physician) and the
anatomy of the lymphatics was characterized almost completely
in the 19th century [12]. The lymphatic vasculature is composed
of a branched network of capillaries and collecting lymphatic ves-
sels that are present in most organs (Fig. 2) [13–15]. Unlike capil-
lary blood vessels, lymphatic capillaries are blind-ended.
Anchoring ﬁlaments attach the lymphatic endothelial cells (LECs)
of the capillary to the extracellular matrix (ECM) and prevent ves-
sel collapse under the conditions of increased interstitial pressure.
Small capillaries drain into pre-collecting and collecting vessels,
which join the thoracic duct or the right lymphatic trunk. Ulti-
mately, lymph is returned to venous circulation at the junctions
with subclavian vein. Lymphatic capillaries have sparse and dis-
continuous basement membrane and they lack pericytes. In con-
trast, collecting lymphatic vessels are covered with continuous
basement membrane and smooth muscle cells (SMCs). Collecting
lymphatic vessels are composed of series of functional units, called
lymphangions, separated by intraluminal valves. Lymphatic valves
are necessary for ensuring unidirectional lymph ﬂow; they consist
of two semilunar leaﬂets, covered on both sides by a specialized
endothelium anchored to the ECM [16]. High lymph pressure
upstream of a valve opens the valve and enables lymph ﬂow,
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Fig. 1. Schematic structure of connexins, connexons and gap junction channels. Connexins are transmembrane proteins that are inserted in the membrane as hexamers.
These hexamers can function as hemichannels, or connexons, which allow diffusion of small molecules from the cytosol towards the extracellular space or vice versa.
Alternatively, a connexon can dock to a connexon expressed by a neighbouring cell to form a gap junction channel. Gap junction channels allow direct intercellular exchange
of small molecules.
Fig. 2. Anatomy of the lymphatic vasculature. Lymph is collected by lymphatic
capillaries which lack a basement membrane and have discontinuous intercellular
junctions. Subsequentely, the lymph ﬂows via pre-collecting lymphatic vessels into
lymphatic collecting vessels. Collecting lymphatic vessels have a basement mem-
brane, are surrounded by smooth muscle cells and contain intraluminal lymphatic
valves that ensure unidirectional lymph ﬂow. After being ﬁltered by lymph nodes
along its way, the lymph returns to the blood circulation at points where larger
lymphatic trunks empty into veins in the jugular region.
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each other thereby closing the valve. Opening and closure of valves
thus depend on periodic changes of ﬂuid pressure gradients within
collecting vessels. Lymph propulsion along the lymphatic network
is regulated by rhythmic compression and expansion of lymphatic
vessels by surrounding tissues and intrinsic pump forces, gener-
ated by the spontaneous phasic contractility of SMCs that cover
each lymphangion. SMC contractions are controlled by nitric oxide,
which regulates the lymphatic pump, as well as by hormones and
prostanoids [17,18]. The primary function of the lymphatic system
is thus to provide an accessory route for getting the excess of inter-
stitial ﬂuid resulting from (blood) capillary ﬁltration (approx. 3 -
liters per day) returned to the blood.
The lymph ﬂows through nodes on its way to returning to the
blood. Lymph nodes are organized structures of lymphoid tissue,
located at intervals along the lymphatic system, containing folliclesof densely packed B and T lymphocytes. The number and size of the
follicles in a lymph node may expand tremendously upon encoun-
tering a foreign antigen. The lymph transports antigen-presenting
cells, e.g. dendritic cells, from peripheral tissues to the lymph
nodes where an immune response is initiated. In fact, afferent
lymph vessels enter at all parts of the periphery of the lymph node,
the lymph penetrates through the substance of the lymph node,
and is drained out by an efferent lymph vessel. These vessels
export immune effector cells and humoral response factors into
the blood circulation [13]. Similarly, tumor cells metastasize
through the lymphatic vessels to draining lymph nodes. Tumor-
draining sentinel lymph nodes are nowadays generally accepted
as prognostic marker for the severity of disease, in particular for
breast cancer and melanomas [19].
Finally, lymphatic vessels are also important in lipid metabo-
lism, as lymphatic capillaries in the villi of the small intestine
(lacteals) take up dietary lipids in the form of chylomicrons and
transport them to the blood circulation via the thoracic duct [20].
Lacteals are also crucial for the uptake of lipid soluble vitamins
A, D, E and K from the digestive system. Additional emerging roles
that link lymphatic vasculature to the control of cardiovascular
function and disease include reverse transport of cholesterol
[21,22] and control of hypertension [23]. In summary, the anatomy
of lymphatic vessels is ﬁrmly established and the role of lymphat-
ics in the transport of interstitial ﬂuid, immune cells and lipids is
well recognized.
3. ‘Early’ evidence for presence of gap junctions and connexins
in the lymphatic system
As mentioned before, connexins can form connexons and full
gap junction channels. As such, connexins can be involved in auto-
crine and paracrine signaling and can also allow for direct gap
junctional intercellular communication (GJIC). Moreover, it is
increasingly recognized that the connexin interactome involves
not only other connexins but also non-connexin proteins such as
endothelial nitric oxide synthase (eNOS) in blood endothelial cells
[24], the zona occludens-1 (ZO-1) in cardiomyocytes and other
cells [25,26] and mitochondrial proteins in hepatocytes [27].
Indeed, connexin-mediated protein–protein interactions can regu-
late the function of such non-connexin proteins (e.g. eNOS) [24].
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should keep in mind that lymphatics have been severely under-
studied as compared to for example the vast number of studies
focusing on the expression and function of connexins in blood
endothelial cells (BECs). Thus, there are only a few examples of
early studies addressing presence of gap junctions in lymphatic
vessels [28,29]. Almost 30 years ago, Compton and Raviola studied
the structure of the sinus wall in the rabbit popliteal lymph node
by electron microscopy and found that LECs of the marginal sinus
were connected by gap junctions [28]. These gap junctions were
later shown to consist of (at least) Cx43 by immunohistochemistry
[30]. McHale reported already in his PhD thesis in 1976 ‘‘that gap
junctions were evident in electron micrographs of lymphatic ves-
sels’’ [29]. Functional studies on isolated segments of bovine mes-
enteric lymphatics [29] as well as on rat mesenteric lymphatics
in vivo [31] showed that lymphatic vessels display rhythmic, retro-
gradely propagated contractile waves rather similar to those
observed in the blood microcirculation, suggesting synchroniza-
tion of tissue responses by GJIC in lymphatic vessels. Moreover,
the use of (non-speciﬁc) pharmacological inhibitors in experiments
on isolated lymphatic vessels suggested that electrical coupling via
gap junctions plays an important role in the synchronization of
lymphatic contractions [29,32]. Indeed, treatment with heptanol
or oleic acid disrupted propagation of contractions along bovine
mesenteric lymphatics [29] and in rat mesenteric lymphatic ves-
sels [32]. More recently, the presence of connexins in lymphatics
was studied using techniques aimed at mRNA expression [33,34].
Wick et al. studied isolated human dermal microvascular LECs
and compared the connexin mRNA expression to microvascular
BECs. Interestingly, they found that the expression of Cx47, a conn-
exin known to be expressed by oligodendrocytes [35,36], was 5.3-
fold increased in LECs as compared to BECs [33]. Shin et al. also
studied human dermal LECs but used a slightly different approach;
they studied VEGF-A and VEGF-C responsive genes and found that
Cx37 was up-regulated in response to VEGF-A but not in response
to VEGF-C. In summary, ‘early’ studies addressing presence of gap
junctions in lymphatics proposed that gap junctions are indeed
present in this part of the vasculature. Moreover, these studies sug-
gested that the presence of gap junctions in lymphatic vessels is of
functional signiﬁcance using non-speciﬁc inhibitors of gap junction
channels. However, none of the studies addressed functional roles
of a speciﬁc connexin in the lymphatic system in vivo. For that
reason it is interesting to note that expression of Cx37, Cx43 and
Cx47 by LECs has recently been shown in vivo [10,11]. Importantly,Table 1
Overview of connexins detected in lymphatics during development and adult life accordin
forming cells.
Developmental
stage
Cx37
E12.5 JLS +
E13.5 JLS +
E15–E16 Early LVCs ++
E16.5 Dermal capillaries +
E17.5 Mesenteric lymphangion +
E18.5 Thoracic duct, lymphangion +
Mesenteric collecting
lymphatics
Submucosal lymphatics
P3–7 Mesenteric collecting
lymphatics
+(enriched at lymphatic
valves)
3–4 weeks old Mesenteric collecting
lymphatics
+(in valves)
Adult Lymphangion (EC) +
Valves (EC) +these two recent studies have started to unravel the functional
consequences of connexin expression in LECs during embryogene-
sis but also in the adult lymphatic vasculature [10,11], and several
critical transcription factors implicated in the regulation of conn-
exin expression by LECs have been identiﬁed [10,11]. The results
of these studies are discussed below.
4. In vivo expression of lymphatic connexins
Until recently, no detailed in vivo data was available onto conn-
exin expression patterns in lymphatic vasculature. In 2011, Kanady
et al. compared the expression of connexins in mouse embryos,
newborn and adult mice [11]. Interestingly, the authors reported
variable expression of Cx37, Cx43 and Cx47 throughout the devel-
oping lymphatic system and noted that all three connexins slowly
(from E16.5 to three weeks after birth) became enriched at valves
in lymphatic mesenteric collecting vessels (Table 1). Surprisingly,
Cx37 and Cx43 displayed a highly segregated expression pattern
in the endothelium of these valves; Cx37 was expressed on the
downstream side of the valves, whereas Cx43 was expressed on
the upstream side of the valves. In addition, heterogeneous Cx47
was observed in embryonic collecting vessels, and Cx47 was
expressed in a small subset of endothelial cells covering the up-
stream side of the adult valve and was thus co-expressed with
Cx43 [11]. Importantly, Sabine et al. observed a differential expres-
sion pattern during the earliest stages of valve formation: Cx37
expression was upregulated in a subset of lymphatic valve-forming
cells while Cx43 levels were lower in these cells than in the rest of
the maturing lymphatic [10]. Remarkably, the highly separated
expression of Cx37 and Cx43 was maintained long after birth as
is was also observed in valves of the thoracic duct in adult
mice [11].5. Cx37 and Cx43 are involved in the formation of lymphatic
system
As Cx37 and Cx43 are highly expressed in LECs during develop-
ment of the lymphatic system, Kanady et al. took advantage of
genetically engineered mice to study the role of Cx37 and Cx43
during lymphatic development [11]. They observed that Cx37-deﬁ-
cient (Cx37/) and Cx37/Cx43/ mice but not Cx43/ mice
exhibited enlarged jugular lymph sacs at E13.5 as compared to
wild-type control mice. Moreover, Cx37/Cx43/ embryos atg to [11] and [10]. EC: endothelial cells. JLS: jugular lymph sac. LVS: lymphatic valve
Cx43 Cx40 Cx47 Cx26 Cx45
+
+    
+
+ + 
+ +
+(in subset of EC, ‘patchy’ expression)
+
+ +(in subset of EC covering lymphatic
valves)
+(in
valves)
+(in subset of EC covering lymphatic
valves)
+    
+ +
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ment and blood-ﬁlled lymphatics [11]. Cx37/, Cx43/ and
Cx37/Cx43/ E18.5 embryos displayed a reduction or even
complete absence of lymphatic valves in mesenteric collecting
lymphatics. Furthermore, the study of Sabine et al. [10] has shown
that the developmental program towards collecting vessels was
successfully initiated in terms of transcription factors but the lym-
phatic valve formation process was incomplete. These two studies
suggest that the observed lymphatic phenotype might at least
partly be due to a reduced valve numbers [10,11]. Strikingly, the
Cx37/Cx43+/ mice showed a decreased postnatal survival due
to chylothorax (milky effusion surrounding the lungs and the
heart), which was accompanied by retrograde lymph ﬂow [11].
Finally, the authors noted that the formation of the valves in the
thoracic duct was also reduced in Cx37/Cx43+/ and therefore
proposed that the chylothorax might be due to a defect in the abil-
ity to move lymph in an anterograde fashion.
6. Regulation of lymphatic valve morphogenesis by connexins
Although Kanady et al. elegantly described in vivo expression of
lymphatic connexins and addressed the consequences of deletion
of these proteins for maintenance of adequate lymphatic function
[11], important questions about the molecular mechanisms still
remained unanswered (e.g. ‘Why do Cx37/ mice lack valves?‘
and ‘Why is the expression pattern of Cx37 in lymphatic valves
so much restricted to the outﬂow side of the valve?’). These ques-
tions were addressed in our recent study focusing on the pathways
controlling lymphatic valve morphogenesis [10]. Formation of
lymphatic valve is a multistep process, initiated at E15.5–E16.0
during embryonic development, when a subset of lymphatic endo-
thelial cells starts to express high levels of transcription factors
Prox1 and Foxc2 in deﬁned locations [37,38]. These lymphatic-
valve forming cells (LVCs) further induce the expression of speciﬁc
ECM components, such as laminin alpha5, and down-regulate the
expression of typical lymphatic capillary endothelial markers, such
as neuropilin-2 and LYVE-1, suggesting acquisition of a speciﬁc
‘‘valve’’ identity [10] LVCs further establish a deﬁned valve terri-
tory, reorient and change their polarity, and migrate inside the
lumen, to form lymphatic valve leaﬂets. Highly coordinated, collec-
tive cell behavior appears to be important for almost all stages of
lymphatic valve formation, therefore it likely involves extensive
cell–cell communication. In line with Kanady et al. [11], Cx37
was found to be expressed in embryonic lymphatic vessels but,
importantly, it was strongly up-regulated in early LVCs to the level
of its expression in nearby arteries shortly after the induction of
Prox1 [10]. Cx43 was also expressed at this developmental phase
in embryonic lymphatic endothelium of the future lymphangion
but its expression level was reduced in comparison to other LECs
in the vessel [10]. Finally, Cx40 could not be detected in lymphatic
endothelium at all developmental stages [10,11]. Thus, Cx37 was
detected in developing lymphatic valves in both studies [10,11],
but the mechanism causing the expression of this protein speciﬁ-
cally in the valves remained elusive. It should be noted that Cx37
expression in arterial ECs is highly sensitive to shear stress [39]. In-
deed, the high laminar shear stress (HLSS) observed in straight
parts of the arteries induces Cx37 expression, whereas Cx37
expression is down-regulated in areas of low laminar shear stress
(LLSS) and oscillatory shear stress (OSS) that are subject to athero-
sclerotic plaque formation [39]. The induction of Cx37 by HLSS in
arterial endothelium is mediated by the transcription factor KLF2
[39]. In contrast to arterial Cx37, the expression of Cx37 in LECs
was up-regulated by OSS in a Prox1/Foxc2-dependent manner
whereas expression of Cx43 was repressed [10]. This observation
goes well with the fact that lymphatic ﬂow turbulent patterns inthe valve sinus are observed in vivo (see movie S3 in [10]). The
up-regulation of Cx37 was accompanied by accumulation of
NFATc1 into the nucleus, indicating activation of Ca2+/calcineu-
rin/NFAT signaling pathway [10]. Interestingly, it has been shown
previously that Cx45 acts upstream of calcineurin/NFAT signaling
during heart valve formation [40]. Therefore, a possible contribu-
tion of Cx37 to calcineurin/NFAT signaling in response to OSS
was investigated using siRNA knock-down approach. OSS induced
uniform nuclear translocation of NFATc1 in control cultures, while
OSS induced a patchy pattern of nuclear NFATc1 accumulation in
LECs with reduced levels of Cx37 (Fig. 3) [10]. Interestingly, siR-
NA-mediated depletion of Prox-1 or Foxc2 resulted in a complete
inhibition of the effect of OSS. In summary, this mechanistic
in vitro analysis [10] shows that (i) Prox-1/Foxc2 and OSS act
upstream of Cx37 whereas Cx37 acts upstream of NFAT signaling
and (ii) diffusion of a signal (e.g. Ca2+) via gap junctions composed
of Cx37 is required to uniformly transmit calcineurin/NFAT activa-
tion throughout the population of cells and to initiate valve forma-
tion in vivo. A recent study demonstrated that planar cell polarity
(PCP) pathway is essential for re-orientation of LVCs, and Ca2+/cal-
cineurin/NFAT is activated in non-canonical Wnt signaling, impli-
cated in PCP in other systems [41,42]. Therefore, downstream
effectors of Cx37/Ca2+/calcineurin/NFAT in LVCs may also include
PCP signaling components.
In conclusion, recent studies have demonstrated that functional
expression of connexins by LECs can be observed in embryonic and
adult mice (reviewed in [43]). Moreover, analyses of genetic mod-
els have shown that at least Cx37 and Cx43 are implicated in for-
mation of lymphatic valves. However, many important questions
have not been answered yet, e.g.: ‘Does the expression of connex-
ins by LECs result in functional GJIC between LECs and if so, which
connexins are involved?’, ‘Do connexins in LECs function as con-
nexons?‘ and ‘Does expression of Cx47 in a relatively small subset
of LECs covering the lymphatic valves affect lymphatic function?’).
These questions should be the focus of future studies. Nonetheless,
from a clinical point of view, it is interesting to note that Cx37 and
Cx43 deﬁcient mice develop malformation of lymphatic vessels,
suggesting that they may be also implicated in human diseases
of lymphatic vessels, such as lymphedema.
7. Connexin mutations in lymphedema
Several diseases e.g. lymphangitis (caused by bacterial infec-
tion) and ﬁlariasis (caused by an infection with thread-like worms)
target the lymphatic vascular system [44,45]. Lymphedema is
however by far the most common disease affecting lymphatics
[13]. Lymphedema can be inherited (primary lymphedema; further
subdivided into congenital lymphedema, lymphedema praecox
and lymphedema tarda) or caused by e.g. medical treatments, trau-
mas or burns (secondary lymphedema). Irrespective of the cause,
lymphedema patients present with an interstitial accumulation
of protein-rich ﬂuid and subsequent inﬂammation, adipose tissue
hypertrophy and ﬁbrosis. The disease is notoriously difﬁcult to
treat and is currently managed by compression bandages, manual
lymph drainage, surgery or low-level laser treatment. Moreover, it
is associated with signiﬁcant morbidity, both physically and men-
tally, for patients.
Mutations in genes regulating lymphatic development may
result in inherited lymphedema. As survey microarray studies
comparing LECs and BECs identiﬁed several connexins in LECs
[33] and as gap junctions appeared to play a role in the mainte-
nance of lymphatic ﬂow [10,11,29,32], Ferrel et al. sequenced
GJA1 (gene encoding Cx43), GJA4 (gene encoding Cx37) and GJC2
(gene encoding Cx47; previously also called Cx46.6 or GJA12) in a
group of families with dominantly inherited lymphedema [46].
Fig. 3. Cx37 is required to synchronize responses to ﬂow in lymphatic endothelial cells. Lymphatic endothelial cells (LECs) cultured in static control conditions display little
nuclear NFATc1 (Nuclear Factor of Activated T cells), while LECs subjected to the oscillatory shear stress, observed in the lymphatic valve sinus in vivo, show increased
accumulation of NFATc1 in the nuclei. The synchronized activation of NFATc1 in response to OSS is lost in absence of Cx37 and only isolated cells display nuclear NFATc1.
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GJC2. The 6 mutations resulted in amino acids changes throughout
the Cx47 protein; i.e. H19P (N-terminus (NT)), S48L (extracellular
loop 1 (EL1)), R125Q and G149S (intracellular loop (IL)), R260C
(extracellular loop 2 (EL2)) and P316L (C-terminus (CT)). Only
one of these mutations (G146S) has previously been linked to a ge-
netic disease, namely Pelizaeus-Merzbacher-like disease (PMLD), a
hypomyelinating leukoencephalopathy [47]. The functional conse-
quences of the Cx47-G149S mutation have been studied after
transfection in communication-incompetent HeLa cells and OLI-
neu cells [48]. As compared to wild-type Cx47 the mutated protein
showed increased ER localization but also formed gap junctional
plaques at the membrane. Functional characterization in Xenopus
Laevis oocytes revealed no signiﬁcant change of resting membrane
potential between wild-type and G149S-mutated Cx47. However,
signiﬁcantly reduced transmembrane currents, indicating reduced
hemi-channel currents, were observed in oocytes injected with
Cx47-G149S cRNA [48]. The lymphedema-related mutations pres-
ent in the ELs seem of particular interest since these are predicted
to interfere with connexon–connexon docking and may thus result
in the absence of GJIC. The linkage between primary lymphedema
and the Cx47-S48L mutation was also found in a second indepen-
dent study on patients with four-limb lymphedema [49].
Genes involved in primary lymphedema could modulate sec-
ondary lymphedema as well. For example, a mutation in the
high-afﬁnity receptor for hepatocyte growth factor was reported
in a patient with primary lymphedema and an unrelated patient
with secondary lymphedema [50]. Indeed, Cx47 mutations have
also been identiﬁed in individuals with secondary lymphedema
following breast cancer treatment [51]. One mutation was already
known from primary lymphedema and PMLD (G146S), three new
GJC2mutations were identiﬁed [51] leading to amino acid changes
in the IL (G183C) and the CT (P381S and H409Y) of Cx47. Finally, a
polymorphism in GJC2 was detected. This polymorphism occurredhowever in secondary lymphedema patients, breast cancer
patients and non-breast cancer controls with similar frequency
[51]. The functional consequences of the four mutations linked
to secondary lymphedema have been studied after transfection
in HeLa cells [51]. By immunoﬂuorescence, the intercellular junc-
tional plaques were indistinguishable between mutant-transfec-
ted and wild-type Cx47-transfected HeLa cells. The authors
reported that Cx47-G183C-transfectants displayed increased elec-
trical coupling as compared with the wild-type Cx47 transfec-
tants, whereas cells transfected with the mutations located in
the CT (P381S and H409Y) were not functionally different from
wild-type Cx47 transfectants. However, this result should be
interpreted with caution as the dual voltage-clamp method is
known to be subject to considerable errors in junctional conduc-
tance induced by series resistance (when electrical coupling be-
tween cells is large) [52]. Interestingly, a missense mutation in a
second connexin (i.e. GJA1) has recently been linked to primary
lymphedema. This novel K206R variant of Cx43 was found in a
three generation family with oculodentodigital dysplasia (ODDD)
and primary lymphedema in the United Kingdom [53]. Of note,
ODDD is an autosomal dominant disorder with abnormalities
affecting the eye, dentition and digits of hands and feet that is
well-known for its association to GJA1 [54]. As Cx47 is co-ex-
pressed with Cx43 in lymphatic endothelium, future studies
should not only include investigations on the distribution and
functional properties of lymphedema-linked mutations on Cx47/
Cx47 homotypic, but also on Cx47/Cx43 heterotypic gap junctions,
similar as is currently done for PMLD-linked mutations [55,56].
In summary, various GJC2 mutations and one GJA1 mutation
have been linked to primary and secondary lymphedema in vari-
ous families and populations. The search for novel mutations in
GJC2 and GJA1, and possibly also in GJA4, should be intensiﬁed as
results from such clinical studies will be of major importance for
patient stratiﬁcation.
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Connexins have been the subject of a vast number of studies in
cardiovascular physiology and pathology [8,57–60]. However, until
recently the expression patterns and functions of connexins in the
lymphatic system remained elusive. Lately, various studies have
addressed the expression of connexins along the lymphatic tree.
These studies, which took the advantage of genetically engineered
mice (which lack for example Cx37), have clearly shown that at
least Cx37 and Cx43 are of importance for the development of
the lymphatic system [10,11]; i.e. both proteins are implicated in
the initial development of the jugular lymph sac and, importantly,
in the formation of lymphatic valves. The expression of Cx37 in
LVCs has also been assessed in a more mechanistic manner [10]:
i.e. Cx37 expression is induced by Prox-1, Foxc2 and OSS. More-
over, gap junctions formed by Cx37 are required to synchronize re-
sponses to ﬂow in cultured LECs; in the absence of Cx37 OSS
activated NFATc1 only in a few cells of the culture, whereas in
presence of Cx37 OSS induced uniform nuclear NFATc1 throughout
the cell monolayer. Taken together, these studies strongly suggest
that connexins might also be implicated in lymphatic function and
disease in humans. Indeed, mutations in connexin (most notably in
the gene coding for Cx47) have recently been linked to primary and
secondary lymphedema (see e.g. [46,51,53]). However, there are
important issues that still have to be addressed. It remains, for
example, unclear whether connexins are only of importance in
the regulation of lymphatic ﬂow (probably via their role in the for-
mation of lymphatic valves) or whether they also affect other lym-
phatic functions? Speciﬁcally, do connexins affect uptake of lipids
from the gut? Or, do connexins affect immune responses mediated
via the lymphatic system? How do the lymphedema-associated
mutations affect connexin function? Do lymphatic connexins play
a role in human diseases, such as tumor metastasis, atherosclerosis
and hypertension? And, most importantly, can we target connexins
for the treatment of lymphatic disorders such as lymphedema?
Answering these questions is exciting; it will provide new insights
in an, until recently, mainly overlooked ﬁeld: the biology of lym-
phatic connexins.Acknowledgements
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